Grace Halsey

Grace Halsey is a health journalist with over six years of experience. She has written extensively on various medical topics, including dermatology, gastroenterology, and endocrinology. Her articles often provide in-depth information about the latest treatments and diagnostic techniques for different conditions. Grace's work focuses on making complex medical concepts accessible to a general audience while maintaining accuracy and credibility. She has been published in several reputable online platforms such as Patient Care Online, where she currently contributes her expertise.

Biography:  https://www.patientcareonline.com/authors/grace-halsey

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

75%

Examples:

  • The greatest increase, more than 600,000, was recorded between 2019 and 2023 due to expanded approval for chronic weight management.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

GLP-1 Receptor Agonists Shift from Diabetes to Obesity Treatment: Implications and Trends

GLP-1 Receptor Agonists Shift from Diabetes to Obesity Treatment: Implications and Trends

Broke On: Tuesday, 23 July 2024 Since around 2020, GLP-1 receptor agonists (GLP-1 RAs) have seen a notable shift from treating type 2 diabetes to obesity in the US. This trend is driven by FDA approvals and the high prevalence of obesity, accounting for over 88% of new prescriptions being semaglutide. However, this shift raises concerns about potential drug shortages and disparities in access.